BigBearai Holdings Inc vs Bristol-Myers Squibb Co — how do they compare? BigBearai Holdings Inc trades at $3.35 (market cap $1.60B), while Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 81.2× BigBearai Holdings Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while BigBearai Holdings Inc pays none. Which is the better fit depends on your goals.
| BBAI | BMY | |
|---|---|---|
Market Cap | $1.60B | $129.94B |
Sector | Technology | Health |
52-Week High | $8.91 | $65.89 |
52-Week Low | $2.61 | $42.60 |
Enterprise Value | $1.30B | $163.92B |
Dividend Yield | — | 3.96% |
Trailing returns across standard periods
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →